# OnCo record camizestrant (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/camizestrant/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "camizestrant" ;
  schema:name "Camizestrant"@en ;
  schema:description "Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows."@en ;
  schema:url <https://onco.cc/drugs/camizestrant/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Camizestrant> ;
  onco:status "approved" ;
  onco:modality "Oral SERD" ;
  schema:alternateName "Etcamah" ;
  onco:approval "US 2026: HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)", "EU 2026: ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026" ;
  onco:acceleratedApproval "US 2026-09-04: In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test" ;
  onco:related <https://onco.cc/pairings/oral-serd-plus-cdk46-after-esr1/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/oral-serd/> ;
  onco:trials <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/trials/nct04644068/>, <https://onco.cc/trials/nct05774951/>, <https://onco.cc/trials/nct07427394/>, <https://onco.cc/trials/nct04711252/>, <https://onco.cc/trials/nct04214288/>, <https://onco.cc/trials/nct06380751/>, <https://onco.cc/trials/nct07647328/> .